The present invention is concerned with novel pyridazinones of formula (I) ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit PDE10A and can be used for the treatment of CNS disorders.